NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$10.5b

Last Updated

2021/04/11 10:22 UTC

Data Sources

Company Financials +

Executive Summary

Alphamab Oncology, a clinical-stage biopharmaceutical company, focuses on the research and development, manufacture, and commercialization of oncology biologics. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Alphamab Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 9966 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 9966's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-1.6%

9966

-3.1%

HK Biotechs

-1.1%

HK Market


1 Year Return

-25.4%

9966

59.2%

HK Biotechs

28.6%

HK Market

Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned 59.2% over the past year.

Return vs Market: 9966 underperformed the Hong Kong Market which returned 28.6% over the past year.


Shareholder returns

9966IndustryMarket
7 Day-1.6%-3.1%-1.1%
30 Day-3.4%2.0%-1.8%
90 Day-24.9%7.1%3.4%
1 Year-25.4%-25.4%59.5%59.2%33.5%28.6%
3 Yearn/a-32.1%-33.3%4.0%-6.9%
5 Yearn/a-0.3%-4.0%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is Alphamab Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alphamab Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 9966 (HK$11.26) is trading below our estimate of fair value (HK$29.27)

Significantly Below Fair Value: 9966 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 9966 is unprofitable, so we can't compare its PE Ratio to the HK Biotechs industry average.

PE vs Market: 9966 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 9966's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 9966 is overvalued based on its PB Ratio (3.9x) compared to the HK Biotechs industry average (3.4x).


Future Growth

How is Alphamab Oncology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

35.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9966 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 9966 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 9966 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 9966's revenue (63.4% per year) is forecast to grow faster than the Hong Kong market (13.3% per year).

High Growth Revenue: 9966's revenue (63.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 9966 is forecast to be unprofitable in 3 years.


Past Performance

How has Alphamab Oncology performed over the past 5 years?

48.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 9966 is currently unprofitable.

Growing Profit Margin: 9966 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 9966's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 9966's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.5%).


Return on Equity

High ROE: 9966 has a negative Return on Equity (-18.82%), as it is currently unprofitable.


Financial Health

How is Alphamab Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: 9966's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥329.5M).

Long Term Liabilities: 9966's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥36.9M).


Debt to Equity History and Analysis

Debt Level: 9966's debt to equity ratio (9.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 9966's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 9966 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 9966 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Alphamab Oncology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 9966's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 9966's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 9966's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 9966's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 9966's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Ting Xu (47 yo)

2.5yrs

Tenure

Dr. Ting Xu, Ph.D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008. Dr. Xu serves as Executive Director at Alphamab Oncology since ...


Leadership Team

Experienced Management: 9966's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: 9966's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alphamab Oncology's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alphamab Oncology
  • Ticker: 9966
  • Exchange: SEHK
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$10.527b
  • Shares outstanding: 934.94m
  • Website: https://www.alphamabonc.com

Number of Employees


Location

  • Alphamab Oncology
  • Building C23
  • Rooms 401 and 501
  • Suzhou
  • Jiangsu Province
  • China

Listings


Biography

Alphamab Oncology, a clinical-stage biopharmaceutical company, focuses on the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bisp...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:22
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.